Molecular Markers in Cervical Cancer Screening in the Feasibility of the Mathematical Markov Model Analysis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2009 by Wuhan University.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Wuhan University
ClinicalTrials.gov Identifier:
NCT00889902
First received: April 27, 2009
Last updated: NA
Last verified: April 2009
History: No changes posted
  Purpose

The purpose of this study is to:

  1. make p16INK4A as a cervical cancer screening of tumor markers, cytology improve existing diagnostic sensitivity, specificity, repeatability and validity, so as to effectively prompted the early discovery and diagnosis of cervical cancer.
  2. reduce screening costs, screening and benefits into quantitative evaluation, for our country to develop cervical cancer prevention and control strategy to provide a reliable theoretical basis.

Condition
Cervical Cancer

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Molecular Markers in Cervical Cancer Screening in the Feasibility of the Mathematical Markov Model Analysis

Resource links provided by NLM:


Further study details as provided by Wuhan University:

Biospecimen Retention:   Samples With DNA

Cervical exfoliated cells


Estimated Enrollment: 200
Study Start Date: April 2009
Estimated Study Completion Date: July 2011
Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Detailed Description:
  1. To carry out large-scale prospective randomized controlled clinical study to evaluate the "cytological molecular markers Detect + P16INK4A" methods of screening accuracy and reliability, as well as the screening method of the biological effects.
  2. Markov set up mathematical model of screening tests to quantify the inputs and the evaluation proceeds. With a view to optimize and perfect a simple, convenient, practical and efficient program of cervical cancer screening.
  Eligibility

Ages Eligible for Study:   25 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

residents of a certain town

Criteria

Inclusion Criteria:

  • Married women aged 25 to 65-year-old with risk factors
  • No tumor and pelvic radiation therapy history
  • Non-pregnant women at present
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00889902

Contacts
Contact: Hong B Cai, Doctor 0086-027-67813044 Chb2105@163.com
Contact: Ying J Huang

Locations
China, Hubei
People'S Hospital
Wufeng county, Hubei, China
Sponsors and Collaborators
Wuhan University
Investigators
Study Director: Hong B Cai, Doctor gynecologic oncology department, Zhongnan Hospital of Wuhan University
  More Information

No publications provided

Responsible Party: HB Cai, Wuhan University
ClinicalTrials.gov Identifier: NCT00889902     History of Changes
Other Study ID Numbers: 320.6740
Study First Received: April 27, 2009
Last Updated: April 27, 2009
Health Authority: China: Ethics Committee

Keywords provided by Wuhan University:
Molecular Markers
Cervical Cancer
Screening
Makov

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female

ClinicalTrials.gov processed this record on July 23, 2014